title: The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition.
abstract: Tuberin, a tumor-suppressor protein produced by the tuberous sclerosis gene TSC2, downregulates the Rheb-mTOR-S6K pathway (mTOR axis). Comparison of the effects of human tuberin mutations, such as G1556S, suggests that pathways other than the mTOR axis might also be involved in the pathogenesis of tuberous sclerosis. Here we test this possibility using the rat G1556S-type mutation (GSM) and a transgenic Eker (Tsc2 mutant) rat system. Cells expressing GSM-tuberin failed to downregulate the mTOR axis. GSM-tuberin had an altered localization, which underlie its reduced ability to form a complex with hamartin, and a site-specific alteration in phosphorylation status indicating diverse regulation by Akt. GSM-transgenic (GSM-Tg) rats exhibited suppression of macroscopic renal tumors following N-ethyl-N-nitrosourea treatment. Intriguingly, rats with weaker GSM-Tg expression showed microscopic cystic and pre-tumorous lesions that were restricted in size and expansion, although they had hyper-phosphorylation of ribosomal protein S6. These results highlight a novel pathway involving tuberin that regulates tumor suppression independently of the mTOR inhibitory function. Identification of such a novel pathway will provide clear implications for generation of new therapeutic targets in the treatment of these tumors.
authors.affiliation: Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Shiono
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: R
authors.initials: R
authors.lastname: Takahashi
authors.forename: G
authors.initials: G
authors.lastname: Sun
authors.forename: M
authors.initials: M
authors.lastname: Abe
authors.forename: D
authors.initials: D
authors.lastname: Zhang
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Piao
authors.forename: Y
authors.initials: Y
authors.lastname: Takagi
authors.forename: R
authors.initials: R
authors.lastname: Mineki
authors.forename: H
authors.initials: H
authors.lastname: Taka
authors.forename: N
authors.initials: N
authors.lastname: Tada
authors.forename: S
authors.initials: S
authors.lastname: Sonobe
authors.forename: S
authors.initials: S
authors.lastname: Momose
authors.forename: M
authors.initials: M
authors.lastname: Ueda
authors.forename: O
authors.initials: O
authors.lastname: Hino
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D001483:Base Sequence; D002460:Cell Line; D005998:Glycine / Q000235:genetics / Q000378:metabolism; D009154:Mutation / Q000235:genetics; D011494:Protein Kinases / Q000378:metabolism*; D051381:Rats; D012694:Serine / Q000235:genetics / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism*
chemical_list: C000624653:TSC2 protein, human; C000624655:Tsc2 protein, rat; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; D012694:Serine; D011494:Protein Kinases; C546842:MTOR protein, human; C546845:mTOR protein, rat; D058570:TOR Serine-Threonine Kinases; D005998:Glycine